10/19/2005 5:12:55 PM
RALEIGH, N.C.--(BUSINESS WIRE)--March 3, 2005--Grant Life Sciences Inc. (OTC Bulletin Board: GLIF) today announced an agreement with Allogen Laboratories, a wholly owned subsidiary of the Cleveland Clinic Foundation, wherein Allogen will perform testing and validation studies on Grant's protein-based HPV/cervical cancer diagnostic technology and kits.
As a part of the agreement, Allogen will screen pre-cancerous and cervical cancer patient samples with Grant's proprietary test to determine the efficacy of the technology. The test, which consists of synthetic peptides derived from human papillomavirus (HPV) proteins, would be the first diagnostic to directly detect cervical cancer.
comments powered by